Evidence map›Paper›PMID 35833031›Full record

ArticleFrontiers in pharmacology2022

A Single Nucleotide Mixture Enhances the Antitumor Activity of Molecular-Targeted Drugs Against Hepatocellular Carcinoma.

Da Mao, Meihong Xu, Qiyu Jiang, Huiwei Sun, Fang Sun, Ruichuang Yang, Yantao Chai, Xiaojuan Li, Boan Li, Yong Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Da MaoDepartment of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Meihong XuDepartment of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Qiyu JiangDepartment of Infectious Disease, Institute of Infectious Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Huiwei SunDepartment of Infectious Disease, Institute of Infectious Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Fang SunDepartment of Infectious Disease, Institute of Infectious Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Ruichuang YangDepartment of Infectious Disease, Institute of Infectious Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yantao ChaiDepartment of Clinical Laboratory, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Xiaojuan LiDepartment of Infectious Disease, Institute of Infectious Disease, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Boan LiDepartment of Clinical Laboratory, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yong LiDepartment of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing, China.
Chinese PLA General Hospital · CNPeking University · CNNational Institute of Metrology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New strategies for molecular-targeted drug therapy for advanced hepatocellular carcinoma (HCC) ignore the contribution of the nutritional status of patients and nutritional support to improve physical status and immunity. We aimed to elucidate the role of a single nucleotide mixture (SNM) in the anti-tumor therapy of HCC, and to explore the importance of a SNM as adjuvant therapy for HCC. Compared with a lipid emulsion (commonly used nutritional supplement for HCC patients), the SNM could not induce metabolic abnormalities in HCC cells (Warburg effect), and did not affect expression of metabolic abnormality-related factors in HCC cells. The SNM could also attenuate the lymphocyte injury induced by antitumor drugs

Indexed as

hepatocellular carcinomaimmune-checkpoint inhibitormolecular-targeted therapynutritional and supportive treatmentsingle nucleotide mixturetyrosine-kinase inhibitor

Identifiers

PMID35833031
PMCPMC9271877
OpenAlexW4283586778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.